# Silara Medtech

> Silara Medtech develops structural heart devices, with a public identity linked to the former Direct Flow Medical valve business. Its distinguishing engineering approach is a polymer-supported, retrievable transcatheter valve; a 2026 paper describes a small feasibility study of a Silara system for pure aortic regurgitation. Historical Direct Flow approvals and financing should not be treated as current Silara commercial status.

- **Founded:** 2017
- **Headquarters:** Santa Rosa, United States
- **Products:** Direct Flow Medical Transcatheter Aortic Valve System (legacy), Silara TAVR system, Implant delivery and annuloplasty technologies
- **Notable:** Legacy Direct Flow received a CE mark in January 2013., Legacy DISCOVER reported 90% survival at one year in 100 enrolled patients., A 2026 JACC: Asia feasibility report evaluated the Silara system for pure aortic regurgitation.

## Products & services

- **Direct Flow Medical Transcatheter Aortic Valve System (legacy)** — Nonmetallic bovine-pericardial valve with an inflatable double-ring support, repositioning and retrieval before permanent release. Received a European CE mark in January 2013; original manufacturer closed in 2016.
- **Silara TAVR system** — Fully retrievable polymer-supported system studied for severe pure aortic regurgitation in a six-patient, single-center feasibility study published in March 2026. Publication does not establish broad commercial approval.
- **Implant delivery and annuloplasty technologies** — Patent applications assigned to Silara cover implant delivery systems and release of annuloplasty implants; these are development records, not proof of marketed products.

## Achievements

- Legacy Direct Flow received a CE mark in January 2013.
- Legacy DISCOVER reported 90% survival at one year in 100 enrolled patients.
- A 2026 JACC: Asia feasibility report evaluated the Silara system for pure aortic regurgitation.
- European patent publications in 2025 and 2026 list Silara as applicant for delivery and annuloplasty technologies.

## Latest updates

- **2026-03** — JACC: Asia published a six-patient feasibility study of the Silara TAVR system for pure aortic regurgitation, with five patients completing at least full one-year follow-up.
- **2026-04** — EP4518803A4 was published for systems and methods for release of an annuloplasty implant, listing Silara Medtech Inc. as applicant.

## Links

- Website: http://www.directflowmedical.com
- LinkedIn: https://www.linkedin.com/company/direct-flow-medical
- Facebook: https://facebook.com/pages/Direct-Flow-Medical-Inc/110553752341233

---

Profile page: https://yespress.io/silara-medtech
Published by YesPress — https://yespress.io
Last updated: 2026-10-03